This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
by Zacks Equity Research
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.
GSKNegative Net Change KRYSPositive Net Change FULCPositive Net Change CVACNo Net Change
biotechs
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
by Ahan Chakraborty
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
NVSPositive Net Change RHHBYNegative Net Change PFENegative Net Change LLYPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
by Zacks Equity Research
BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
by Zacks Equity Research
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
REGNPositive Net Change SNYPositive Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechs medical pharmaceuticals
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
by Kinjel Shah
VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
VRTXPositive Net Change MRNANegative Net Change CRSPNegative Net Change
biotechs
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints
by Zacks Equity Research
The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.
AMGNPositive Net Change KRYSPositive Net Change FULCPositive Net Change VRDNPositive Net Change
biotechs
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
by Zacks Equity Research
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
BMYNegative Net Change MRKNegative Net Change CRVSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
by Zacks Equity Research
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change TERNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Relay Stock Soars on Upbeat Data From Breast Cancer Study
by Zacks Equity Research
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
AZNPositive Net Change NVSPositive Net Change PFENegative Net Change RLAYPositive Net Change
biotechnology biotechs medical pharmaceuticals
RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study
by Zacks Equity Research
The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.
ILMNPositive Net Change KRYSPositive Net Change RZLTNegative Net Change FULCPositive Net Change
biotechs
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
by Zacks Equity Research
The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.
NVSPositive Net Change CALTPositive Net Change TVTXPositive Net Change
biotechs medical pharmaceuticals
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
by Zacks Equity Research
The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.
ILMNPositive Net Change RCKTPositive Net Change KRYSPositive Net Change FULCPositive Net Change
biotechs
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
by Zacks Equity Research
Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.
ILMNPositive Net Change KRYSPositive Net Change FULCPositive Net Change IMVTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
by Zacks Equity Research
Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
SNYPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
by Zacks Equity Research
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
ILMNPositive Net Change KRYSPositive Net Change HOTHNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
PFENegative Net Change MRNANegative Net Change KRYSPositive Net Change BNTXNegative Net Change
biotechs
Why Biotech ETFs Are Beating the Market
by Neena Mishra
: Biotech stocks are poised to benefit from lower rates
REGNPositive Net Change GILDPositive Net Change IBBPositive Net Change XBIPositive Net Change SBIOPositive Net Change
biotechnology biotechs cancer cell-therapy etfs
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
by Zacks Equity Research
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.
JAZZPositive Net Change AXSMPositive Net Change KRYSPositive Net Change FULCPositive Net Change
biotechs
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
by Zacks Equity Research
BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.
BMRNPositive Net Change ARCTPositive Net Change FULCPositive Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
by Zacks Equity Research
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
REGNPositive Net Change RHHBYNegative Net Change MRKNegative Net Change BAYRYPositive Net Change
biotechs medical pharmaceuticals
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
by Zacks Equity Research
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
ALNYPositive Net Change NVAXNegative Net Change PNo Net Change PCVXPositive Net Change ATHAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Amgen Stock Rises Almost 20% in 6 Months: Buy, Sell or Hold?
by Kinjel Shah
AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechs
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
by Zacks Equity Research
BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
BIIBPositive Net Change ILMNPositive Net Change IONSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
by Zacks Equity Research
DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.
DYNPositive Net Change EXELPositive Net Change SRPTPositive Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
by Zacks Equity Research
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
BIIBPositive Net Change EXELPositive Net Change KRYSPositive Net Change DNLIPositive Net Change
biotechnology biotechs pharmaceuticals